» Articles » PMID: 29117898

The Contribution of Immune Infiltrates and the Local Microenvironment in the Pathogenesis of Osteosarcoma

Overview
Journal Cell Immunol
Publisher Elsevier
Date 2017 Nov 10
PMID 29117898
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma is a rare primary bone cancer characterized by cancer cells producing calcified osteoid extracellular matrix and inducing lung metastases with a high frequency. The local microenvironment defined several tumor niches controlling the tumor growth and cell extravasation. The immune infiltrate composes one of these niches. The immune environment of osteosarcoma is mainly composed by T-lymphocytes and macrophages but also contains other subpopulations including B-lymphocytes and mast cells. Osteosarcoma cells control the recruitment and differentiation of immune infiltrating cells and establish a local immune tolerant environment favorable to the tumor growth, drug resistance and the occurrence of metastases. Osteosarcoma cells are able to affect the balance between M1 and M2 macrophage subtypes and so could control the T-lymphocyte responses via the PD-1/PDL-1 system. In addition, mesenchymal stem cells may also contribute to this immune tolerance and strengthen the immune evasion. The present review gives a brief overview of the immune components of osteosarcoma and their most recent therapeutic interests.

Citing Articles

Osteosarcoma: A comprehensive review of model systems and experimental therapies.

Robbins G, Vue Y, Rahrmann E, Moriarity B Med Res Arch. 2025; 12(11).

PMID: 39916749 PMC: 11801376. DOI: 10.18103/mra.v12i11.6000.


Comprehensive analysis of ESCRT transcriptome-associated signatures and identification of the regulatory role of LMO7-AS1 in osteosarcoma.

Zhao S, Tian D, Huang F, Wang L, Cheng J, He Z Cancer Cell Int. 2025; 25(1):29.

PMID: 39885569 PMC: 11783933. DOI: 10.1186/s12935-025-03659-4.


Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models.

Rodrigues J, Sarmento B, Leite Pereira C In Vitro Model. 2025; 1(1):5-27.

PMID: 39872973 PMC: 11756501. DOI: 10.1007/s44164-022-00008-x.


Osteosarcoma biomarker analysis and drug targeting prediction based on pyroptosis-related genes.

Zhuang Y, Li X Medicine (Baltimore). 2025; 104(3):e40240.

PMID: 39833053 PMC: 11749676. DOI: 10.1097/MD.0000000000040240.


Machine learning-based selection of immune cell markers in osteosarcoma: prognostic determination and validation of CLK1 in disease progression.

Zhang N, Haizhen Z, Zhang R, Li X Front Immunol. 2025; 15:1468875.

PMID: 39742274 PMC: 11685004. DOI: 10.3389/fimmu.2024.1468875.